Fujisawa Report issue

Contributed to NME For profit Phase 3
Founded: Osaka Japan (1894)
Status: Acquired by Astellas (2005) → now Leo Pharma (2015)

Organization Overview

First Clinical Trial
1999
NCT00001027
First Marketed Drug
1991
tacrolimus (prograf)
First NDA Approval
1994
tacrolimus (prograf)
Last Known Activity
2005

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Fujisawa GmbH | FUJISAWA HLTHCARE | Fujisawa Pharmaceutical Co

Active Ingredients

Marketed Drugs (4)

adenosine (Adenocard) (NDA)

ceftizoxime (Cefizox) (NDA)

micafungin (mycamine) (2005 NDA)

tacrolimus (prograf) (1994 NDA)

Drugs in Phase 3 Trials (4)

Key: Fujisawa (3) Acquired (1)

dapsone (aczone) (1 trial)

mycophenolate (CellCept) (1 trial)

pentamidine (pentam) (4 trials)

sirolimus (rapamune) (2 trials)

Indications

Approved Indications


 

Candidiasis

Gonorrhea

Meningitis, Haemophilus

Pelvic Inflammatory Disease

Respiratory Tract Infections

Urinary Tract Infections

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 1 (Phase 3)

Diabetic Nephropathies (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Pneumocystis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 4